⌘K
Loading ticker…
As of 2026-08-21, Jade Biosciences, Inc. Common Stock (JBIO) has a 3-month relative strength percentile of 30 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 69. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.3%, relative volume 0.66×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
JBIO is in a stage 2 uptrend, week 3. Currently in a 81-day base; basing ADR 8.0% (broad 7.7%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 2.6% / 22.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
JBIO is held by 15 ETFs as of May 2026. Top owner: VTWO at 0.02% weight, $3M notional. Top 3 carry $6M.
Held by 23 ETFs · $53M across latest filings · largest weight 1.20% (BBC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.02% | $3M | — |
| VFMO | 0.10% | $2M | +0.08 pp |
| AVSC | 0.04% | $1M | +0.02 pp |
| ONEQ | 0.00% | $541K | — |
| VTWV | 0.04% | $533K | — |
| AVUSAvantis U.S. Equity ETF | 0.00% | $107K | new |
| MSSM | 0.01% | $72K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $58K | — |
| OMFS | 0.01% | $40K | — |
| ITWO | 0.02% | $32K | — |
Showing 10 of 15 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JBIO Jan avg: 1.17% median: 1.17% win: 100% σ: 0.00% n: 1 2025-04-30 → 2026-07-31 | JBIO Feb avg: -5.00% median: -5.00% win: 0% σ: 0.00% n: 1 2025-04-30 → 2026-07-31 | JBIO Mar avg: -5.26% median: -5.26% win: 0% σ: 0.00% n: 1 2025-04-30 → 2026-07-31 | JBIO Apr avg: 33.68% median: 33.68% win: 50% σ: 56.55% n: 2 2025-04-30 → 2026-07-31 | JBIO May avg: -18.73% median: -18.73% win: 0% σ: 7.01% n: 2 2025-04-30 → 2026-07-31 | JBIO Jun avg: 21.70% median: 21.70% win: 100% σ: 22.76% n: 2 2025-04-30 → 2026-07-31 | JBIO Jul avg: -19.57% median: -19.57% win: 0% σ: 11.96% n: 2 2025-04-30 → 2026-07-31 | JBIO Aug avg: 9.88% median: 9.88% win: 100% σ: 0.00% n: 1 2025-04-30 → 2026-07-31 (current) | JBIO Sep avg: 9.24% median: 9.24% win: 100% σ: 0.00% n: 1 2025-04-30 → 2026-07-31 | JBIO Oct avg: 13.56% median: 13.56% win: 100% σ: 0.00% n: 1 2025-04-30 → 2026-07-31 | JBIO Nov avg: 30.82% median: 30.82% win: 100% σ: 0.00% n: 1 2025-04-30 → 2026-07-31 | JBIO Dec avg: 20.36% median: 20.36% win: 100% σ: 0.00% n: 1 2025-04-30 → 2026-07-31 |